- ►nih.gov G Anastassiou, N Bornfeld, AO Schueler, H … - British Journal of Ophthalmology, 2006 - bjo.bmj.com Results: Brachytherapy was well tolerated by every patient. The mean applied
dose was 416 Gy at the sclera and 108 Gy at the tumour apex. In all but four
eyes (88.6%), it was possible to control the VTR activity. The median ... Cited by 8 - Related articles - BL Direct - All 7 versions
MA Blasi, A Scupola, AC Tiberti, P Sasso, E … - Retina, 2006 - pdfs.journals.lww.com From *the Department of Ophthalmology, University of L'Aquila, L'Aquila, Italy;
and †Department of Ophthalmology, Catholic University of Rome, Rome, Italy.
Presented in part at the ARVO Meeting [ARVO Abstract 3567], April 28, 2004, ... Cited by 13 - Related articles - BL Direct - All 4 versions
- ►nih.gov B Damato - British Journal of Ophthalmology, 2006 - bjo.bmj.com Patients tend to present with visual loss, floaters, and/or photopsia. On
ophthalmoscopy, the tumour has the appearance of a yellow or pink, intraretinal
mass associated with adjacent hard exudates and occasionally retinal and ... Cited by 5 - Related articles - BL Direct - All 6 versions
N Kenawy, C Groenwald, B Damato - Eye(London. 1987), 2007 - cat.inist.fr Treatment of a vasoproliferative tumour with intravitreal bevacizumab(Avastin).
N KENAWY, C GROENWALD, B DAMATO Eye(London. 1987) 21 ... Cited by 10 - Related articles - BL Direct - All 4 versions
[CITATION] Photodynamic therapy with Verteporfin in subfoveal choroidal neovascularization to central …
